Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)

Inclusion Criteria: * Pathologically proven NSCLC * Ineligibile for curative treatment (namely, stage IIIb or IV) * History of one to three prior systemic chemotherapy tumors without active EGFR mutations (exon 19 deletion, L858R mutation in exon 21) * At least one lesion that was unidimensionally measurable by computed tomography (by RECIST 1.1) * 18 years old or older * Performance status ECOG 0-2 * Adequate organ function as evidenced by the following: * Absolute neutrophil count \> 1.0 x 109/L * Platelets \> 75 x 109/L * Total bilirubin ≤ 1.5 UNL * AST and/or ALT \< 5 UNL * Creatinine clearance ≥ 45mL/min Exclusion Criteria: * Previous EGFR TKI therapy history * Systemic anticancer therapy within the previous 3 weeks * Other invasive malignancy within the past 2 years except non-melanoma skin cancer, in situ cervix cancer, or papillary thyroid cancer * Other concurrent illness that would preclude study participation (severe heart disease) * Other concurrent physical condition (e.g., infectious disease) that would preclude study participation * Pregnant or nursing